Compare KeyCorp (KEY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Sanofi SA — how do they compare? KeyCorp trades at $19.98 (market cap $21.45B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 4.4× KeyCorp's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and Sanofi SA for 94 Days on average.
| KEY | SNY | |
|---|---|---|
Market Cap | $21.45B | $95.18B |
Volume | 19,450,846 | 2,995,646 |
Sector | Financials | Health |
52-Week High | $23.99 | $52.34 |
52-Week Low | $16.78 | $39.51 |
Typical Hold Time | 66 Days | 94 Days |
Enterprise Value | $34.63B | $114.48B |
Dividend Yield | 4.08% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $19.97, up 0.71% with strong recent earnings beats and a 60.79% analyst buy rating. The stock shows bearish technical signals but maintains solid fundamentals with 26.72% net margin and 11.01% ROE. Recent corporate actions include a $0.21 dividend and executive appointments, while cash flow trends show operational stability despite recent net outflows.
KEY presents a compelling value opportunity with 25% upside to consensus target, supported by earnings momentum and dividend stability. Risks include technical bearish pressure, interest rate sensitivity, and competitive dividend landscape. The bank's improved 2026 revenue guidance and institutional accumulation suggest underlying strength despite near-term headwinds.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
